Zacks Research Upgrades Haleon (NYSE:HLN) to "Hold"

Key Points

• Zacks Research upgraded Haleon from “strong sell” to “hold,” while other analysts maintained ratings ranging from “strong buy” to “sell.” MarketBeat’s consensus rating is “Moderate Buy.”
• Haleon shares opened at $9.87, with a 52-week range of $8.65 to $11.28 and a market capitalization of approximately $43.47 billion.
• Institutional investors and hedge funds have generally increased their Haleon holdings, though they collectively own only 6.67% of the company’s stock.

Haleon (NYSE:HLN - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a report issued on Wednesday,Zacks.com reports.

Several other research firms also recently commented on HLN. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Haleon in a research report on Tuesday, August 11th. Morgan Stanley reaffirmed an "overweight" rating on shares of Haleon in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Haleon in a research report on Thursday, April 30th. Wall Street Zen upgraded shares of Haleon from a "hold" rating to a "buy" rating in a report on Sunday, July 12th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Haleon in a research report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Haleon has an average rating of "Moderate Buy".

Haleon Stock Performance

Shares of HLN opened at $9.87 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The stock has a 50 day moving average price of $9.67 and a 200 day moving average price of $9.82. The company has a market capitalization of $43.47 billion, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 1.97 and a beta of 0.12. Haleon has a 52-week low of $8.65 and a 52-week high of $11.28.

Institutional Trading of Haleon

A number of institutional investors and hedge funds have recently modified their holdings of HLN. IHT Wealth Management LLC lifted its position in Haleon by 6.9% in the 4th quarter. IHT Wealth Management LLC now owns 16,205 shares of the company's stock valued at $164,000 after acquiring an additional 1,049 shares in the last quarter. National Bank of Canada FI raised its holdings in Haleon by 6.7% during the third quarter. National Bank of Canada FI now owns 17,385 shares of the company's stock valued at $156,000 after acquiring an additional 1,099 shares during the period. Oppenheimer & Co. Inc. boosted its position in shares of Haleon by 4.7% during the fourth quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company's stock worth $250,000 after acquiring an additional 1,100 shares during the last quarter. Cary Street Partners Financial LLC grew its position in shares of Haleon by 20.1% during the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company's stock valued at $69,000 after purchasing an additional 1,113 shares in the last quarter. Finally, Advisory Services Network LLC boosted its position in shares of Haleon by 7.1% during the 3rd quarter. Advisory Services Network LLC now owns 17,431 shares of the company's stock valued at $156,000 after acquiring an additional 1,155 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

About Haleon

Haleon plc NYSE: HLN is a global consumer healthcare company formed through the separation of a large pharmaceutical group's consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source